Naturally occurring hypoallergenic Bet v 1 isoforms fail to induce IgE responses in individuals with birch pollen allergy

Journal of Allergy and Clinical Immunology

Volumn 121, Issue 1, 2008, Pages 246-252

  Wagner, Stefan ^a   Radauer, Christian ^a   Bublin, Merima ^a   Hoffmann Sommergruber, Karin ^a   Kopp, Tamara ^b   Greisenegger, Elli K ^b   Vogel, Lothar ^c   Vieths, Stefan ^c   Scheiner, Otto ^a   Breiteneder, Heimo ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Universitatsklinik fur Dermatologie   (Austria)

^c PAUL EHRLICH INSTITUT   (Germany)

Author keywords

Bet v 1; Bet v 1.0101; Bet v 1.0401; Bet v 1.1001; birch pollen allergy; hypoallergenic variant; isoforms

Indexed keywords

ALLERGEN; AMINO ACID; BET V 1 ALLERGEN; FC RECEPTOR; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY AFFINITY; ANTIBODY RESPONSE; ARTICLE; BIRCH; CIRCULAR DICHROISM; CONTROLLED STUDY; CROSS REACTION; ENZYME INHIBITION; FEMALE; HUMAN; IMMUNOGENICITY; IMMUNOTHERAPY; MALE; MAST CELL LEUKEMIA; MEDIATOR RELEASE; POLLEN ALLERGY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION;

ADULT; ALLERGENS; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, BLOCKING; BETULA; CELL LINE, TUMOR; CIRCULAR DICHROISM; FEMALE; HUMANS; HYPERSENSITIVITY, IMMEDIATE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PLANT PROTEINS; POLLEN; PROTEIN ISOFORMS; RATS;

EID: 38149102307     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2007.08.006     Document Type: Article

References (22)

1. Strait R.T., Morris S.C., and Finkelman F.D. IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and Fc gamma RIIb cross-linking. J Clin Invest 116 (2006) 833-841
2. Till S.J., Francis J.N., Nouri-Aria K., and Durham S.R. Mechanisms of immunotherapy. J Allergy Clin Immunol 113 (2004) 1025-1034
3. Wing K., and Sakaguchi S. Regulatory T cells as potential immunotherapy in allergy. Curr Opin Allergy Clin Immunol 6 (2006) 482-488
4. Moverare R., Elfman L., Vesterinen E., Metso T., and Haahtela T. Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System. Allergy 57 (2002) 423-430
5. Valenta R. The future of antigen-specific immunotherapy of allergy. Nat Rev Immunol 2 (2002) 446-453
6. Ferreira F., Briza P., Infuhr D., Schmidt G., Wallner M., Wopfner N., et al. Modified recombinant allergens for safer immunotherapy. Inflamm Allergy Drug Targets 5 (2006) 5-14
7. Moverare R., Westritschnig K., Svensson M., Hayek B., Bende M., Pauli G., et al. Different IgE reactivity profiles in birch pollen-sensitive patients from six European populations revealed by recombinant allergens: an imprint of local sensitization. Int Arch Allergy Immunol 128 (2002) 325-335
8. Schenk M.F., Gilissen L.J., Esselink G.D., and Smulders M.J. Seven different genes encode a diverse mixture of isoforms of Bet v 1, the major birch pollen allergen. BMC Genomics 7 (2006) 168
9. Ferreira F., Hirtenlehner K., Jilek A., Godnik-Cvar J., Breiteneder H., Grimm R., et al. Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for immunotherapy. J Exp Med 183 (1996) 599-609
10. Arquint O., Helbling A., Crameri R., Ferreira F., Breitenbach M., and Pichler W.J. Reduced in vivo allergenicity of Bet v 1d isoform, a natural component of birch pollen. J Allergy Clin Immunol 104 (1999) 1239-1243
11. Hartl A., Kiesslich J., Weiss R., Bernhaupt A., Mostbock S., Scheiblhofer S., et al. Isoforms of the major allergen of birch pollen induce different immune responses after genetic immunization. Int Arch Allergy Immunol 120 (1999) 17-29
12. Akdis M., and Akdis C.A. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 119 (2007) 780-791
13. Schwede T., Kopp J., Guex N., and Peitsch M.C. SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Res 31 (2003) 3381-3385
14. Hoffmann A., Jamin A., Foetisch K., May S., Aulepp H., Haustein D., et al. Determination of the allergenic activity of birch pollen and apple prick test solutions by measurement of beta-hexosaminidase release from RBL-2H3 cells: comparison with classical methods in allergen standardization. Allergy 54 (1999) 446-454
15. Breiteneder H., Pettenburger K., Bito A., Valenta R., Kraft D., Rumpold H., et al. The gene coding for the major birch pollen allergen Betv1, is highly homologous to a pea disease resistance response gene. EMBO J 8 (1989) 1935-1938
16. Swoboda I., Jilek A., Ferreira F., Engel E., Hoffmann-Sommergruber K., Scheiner O., et al. Isoforms of Bet v 1, the major birch pollen allergen, analyzed by liquid chromatography, mass spectrometry, and cDNA cloning. J Biol Chem 270 (1995) 2607-2613
17. Gafvelin G., Parmley S., Neimert-Andersson T., Blank U., Eriksson T.L., van Hage M., et al. Hypoallergens for allergen-specific immunotherapy by directed molecular evolution of mite group 2 allergens. J Biol Chem 282 (2007) 3778-3787
18. Bottcher M.F., Jenmalm M.C., and Bjorksten B. Immune responses to birch in young children during their first 7 years of life. Clin Exp Allergy 32 (2002) 1690-1698
19. Reese G., Ballmer-Weber B.K., Wangorsch A., Randow S., and Vieths S. Allergenicity and antigenicity of wild-type and mutant, monomeric, and dimeric carrot major allergen Dau c 1: destruction of conformation, not oligomerization, is the roadmap to save allergen vaccines. J Allergy Clin Immunol 119 (2007) 944-951
20. Hochreiter R., Stepanoska T., Ferreira F., Valenta R., Vrtala S., Thalhamer J., et al. Prevention of allergen-specific IgE production and suppression of an established Th2-type response by immunization with DNA encoding hypoallergenic allergen derivatives of Bet v 1, the major birch-pollen allergen. Eur J Immunol 33 (2003) 1667-1676
21. Reisinger J., Horak F., Pauli G., van Hage M., Cromwell O., Konig F., et al. Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity. J Allergy Clin Immunol 116 (2005) 347-354
22. Gafvelin G., Thunberg S., Kronqvist M., Gronlund H., Gronneberg R., Troye-Blomberg M., et al. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1. Int Arch Allergy Immunol 138 (2005) 59-66